Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients

van Waalwijk van Doorn-Khosrovani, S B; Pisters-van Roy, A; van Saase, L; van der Graaff, M; Gijzen, J; Sleijfer, S; Hoes, L R; van Berge Henegouwen, J M; van der Wijngaart, H; van der Velden, D L; van Werkhoven, E; Retel, V P; van Harten, W H; Huitema, A D R; Timmers, L; Gelderblom, H; Verheul, H M W; Voest, E E

doi:https://doi.org/10.1093/annonc/mdz119

Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients

DSpace/Manakin Repository

Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients

van Waalwijk van Doorn-Khosrovani, S B; Pisters-van Roy, A; van Saase, L; van der Graaff, M; Gijzen, J; Sleijfer, S; Hoes, L R; van Berge Henegouwen, J M; van der Wijngaart, H; van der Velden, D L; van Werkhoven, E; Retel, V P; van Harten, W H; Huitema, A D R; Timmers, L; Gelderblom, H; Verheul, H M W; Voest, E E

(2019) Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, volume 30, issue 5, pp. 663 - 665

(Article)

Download/Full Text

Open Access version via Utrecht University Repository

Publisher version

Version on publisher website for UU-students and staff

Version on publisher website

Keywords: Hematology, Oncology

DOI: https://doi.org/10.1093/annonc/mdz119

ISSN: 0923-7534

Publisher: Oxford University Press

Note: Funding Information: The DRUP trial is supported by the Barcode for Life Foundation (grant number not applicable); the Dutch Cancer Society (grant number 10014); and all participating pharmaceutical companies (grant numbers not applicable): Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Novartis, Merck Sharp & Dohme, Pfizer and Roche. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

(Peer reviewed)